Salarius Pharmaceuticals (Salarius Pharmaceuticals) Debt-to-Equity : 0.06 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Salarius Pharmaceuticals Debt-to-Equity?

Salarius Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.29 Mil. Salarius Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Salarius Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $5.29 Mil. Salarius Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 0.05.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Salarius Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

SLRX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.05 Max: 0.06
Current: 0.06

During the past 10 years, the highest Debt-to-Equity Ratio of Salarius Pharmaceuticals was 0.06. The lowest was 0.02. And the median was 0.05.

SLRX's Debt-to-Equity is ranked better than
69.35% of 1070 companies
in the Biotechnology industry
Industry Median: 0.145 vs SLRX: 0.06

Salarius Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Salarius Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Salarius Pharmaceuticals Debt-to-Equity Chart

Salarius Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.05

0.02

0.06

Salarius Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	0.08	0.06

Competitive Comparison of Salarius Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Salarius Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Salarius Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Salarius Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Salarius Pharmaceuticals's Debt-to-Equity falls into.

Salarius Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Salarius Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.29	+	0)	/	5.287
	=	0.05

Salarius Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.29	+	0)	/	5.287
	=	0.05

Salarius Pharmaceuticals (NAS:SLRX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Salarius Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Salarius Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Salarius Pharmaceuticals (Salarius Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Salarius Pharmaceuticals Inc (NAS:SLRX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

FP1:Germany

Address

2450 Holcombe Boulevard, Suite X, Houston, TX, USA, 77021

Website

https://www.salariuspharma.com

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The Company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

Executives

Tess Burleson	director	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Jonathan I Lieber	director	C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451
William K. Mcvicar	director	C/O INOTEK PHARMACEUTICALS CORPORATION, 131 HARTWELL AVENUE, SUITE 105, LEXINGTON MA 02421
Arnold C Hanish	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Mark J Rosenblum	officer: Exec VP Finance, Interim CFO	3990 SPRING VALLEY ROAD, APT. 1218, DALLAS TX 75244
David J. Arthur	director, officer: Chief Executive Officer	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Scott Jordan	officer: Chief Financial Officer	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Mccreedy Bruce J Jr.	director	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Jonathan P Northrup	director	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Pao-yu Chuang	officer: Controller	2450 HOLCOMBE BLVD., SUITE J-608, HOUSTON TX 77021
Paul Lammers	director	2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380
Boston Foundation, Inc.	10 percent owner	75 ARLINGTON STREET, BOSTON MA 02116
Christoph H Westphal	10 percent owner	C/O ALNYLAM PHARMACEUTICALS, INC, 300 THIRD STREET, CAMBRIDGE MA 02142
Longwood Fund Ii, L.p.	10 percent owner	800 BOYLSTON STREET, SUITE 1555, BOSTON MA 02199
Roger D Tung	director	99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421